Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
Genetic testing company Myriad Genetics (NASDAQ: MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to $190.7 million. The company’s full-year revenue guidance of $780 million at the midpoint came in 9.7% below analysts’ estimates. Its non-GAAP loss of $0.25 per share was significantly below analysts’ consensus estimates. Is now the time to buy Myriad Genetics? Find out by accessing our full research report, it’s free.
How this was made
The 30-second read
Why it matters
Q2 results show a revenue decline and a full-year guidance midpoint below analyst expectations, alongside an adjusted EPS loss that deepened versus the prior-year quarter. The stock’s reported -28.6% reaction suggests the market is repricing both growth and profitability risk.
Market read
Traders can act on a fresh earnings and guidance datapoint that directly resets near-term expectations for MYGN’s revenue trajectory and loss profile.
What to watch
The article emphasizes misses and margins but provides limited detail on whether the volume growth and product submissions translate into improved future revenue quality or reimbursement outcomes.
Background
Myriad Genetics is a genetic testing company focused on oncology and women’s health, with recent emphasis on Cancer Care Continuum initiatives and new test offerings.
Ticker impact
Myriad Genetics reported Q2 CY2026 revenue of $190.7M, down 10.5% YoY, and full-year guidance $780M midpoint, 9.7% below estimates.
Bearish near-term bias, with elevated volatility as the market reprices FY revenue and profitability expectations.
The article provides concrete downside datapoints: revenue decline, guidance below consensus, adjusted EPS loss of -$0.25 missing estimates, and a reported -28.6% stock drop to $3.84 immediately after results.
Market effects
Reinforces investor skepticism toward profitability timelines in genetic testing and oncology diagnostics, potentially pressuring peer valuation multiples.
Primarily US small/mid-cap healthcare sentiment, with limited direct cross-region spillover implied by the article.
Low global relevance beyond US healthcare diagnostics sentiment, as no international regulatory or deal catalysts are mentioned.
Counterpoint
Management highlights Cancer Care Continuum progress, including Prolaris + AI launch and Precise MRD expansion, which could support a rebound if adoption accelerates.
Key entities
- companyMyriad Genetics
Reported Q2 CY2026 revenue of $190.7M (down 10.5% YoY) and FY revenue guidance midpoint of $780M, 9.7% below estimates.
- personSam Raha
CEO quoted on progress across the Cancer Care Continuum, including Prolaris + AI and Precise MRD expansion.
